A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease
Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
This study is an open-label of single transdermal dose of DSP-9632P to evaluate the dopamine
release derived from levodopa in brain, and a randomized, double-blind, placebo-controlled,
2-way crossover of multiple transdermal doses of DSP-9632P to evaluate the safety and
tolerability in patients with levodopa-induced dyskinesia in Parkinson's disease.